Abstract |
Three series of novel 4-benzothiazole amino quinazolines Dasatinib derivatives have been designed and synthesized. The entire target compounds were investigated for their in vitro cytotoxic activity by the MTT-based assay against 6 human cancer cell lines. Compared with the parental Dasatinib, most of the new compounds, especially 2, 4, 6-trimethylaniline series (3), demonstrated significant inhibitory activities against six cell lines. Furthermore, the target compounds were screened for Src and Abl kinase inhibitory activity. Among them, 1a, 1f and 3a-3f are more potential dual Src/Abl kinase inhibitors. Thus they may be promising lead compounds to be developed as an alternative for current Dasatinib therapy or for Imatinib-resistant patients, potentially via simultaneously blocking multiple RTK signaling pathways.
|
Authors | Jin Cai, Min Sun, Xiaoqing Wu, Junqing Chen, Peng Wang, Xi Zong, Min Ji |
Journal | European journal of medicinal chemistry
(Eur J Med Chem)
Vol. 63
Pg. 702-12
(May 2013)
ISSN: 1768-3254 [Electronic] France |
PMID | 23567960
(Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
|
Copyright | Copyright © 2013 Elsevier Masson SAS. All rights reserved. |
Chemical References |
- Antineoplastic Agents
- Benzothiazoles
- Protein Kinase Inhibitors
- Pyrimidines
- Quinazolines
- Thiazoles
- Proto-Oncogene Proteins c-abl
- src-Family Kinases
- benzothiazole
- Dasatinib
|
Topics |
- Antineoplastic Agents
(chemical synthesis, chemistry, pharmacology)
- Benzothiazoles
(chemistry)
- Cell Line, Tumor
- Cell Proliferation
- Cell Survival
- Dasatinib
- Dose-Response Relationship, Drug
- Drug Design
- HCT116 Cells
- Humans
- Inhibitory Concentration 50
- K562 Cells
- Models, Chemical
- Molecular Structure
- Protein Kinase Inhibitors
(chemical synthesis, chemistry, pharmacology)
- Proto-Oncogene Proteins c-abl
(antagonists & inhibitors, metabolism)
- Pyrimidines
(chemistry)
- Quinazolines
(chemical synthesis, chemistry, pharmacology)
- Thiazoles
(chemistry)
- U937 Cells
- src-Family Kinases
(antagonists & inhibitors, metabolism)
|